American Academy of Ophthalmology Meeting

American Academy of Ophthalmology Meeting

Issue: November 2016
October 17, 2016
1 min read

Topical NSAID prevents pseudophakic CME in eyes with certain risk factors

Issue: November 2016
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

CHICAGO — The use of once-daily 0.3% nepafenac after cataract surgery can help prevent pseudophakic cystoid macular edema in eyes with certain risk factors, but did not improve PCME outcomes in eyes without those risk factors, according to a presenter here.

“We are able to show we had a significantly improved PCME outcome with risk factors. This is, in the general ophthalmology practice, about 10% to 30% of patients. However, in 70% to 90% of the patients, it is unlikely that clinical PCME outcomes are improved in those patients without risk factors,” Sean J. McCafferty, MD, said at the American Academy of Ophthalmology meeting.

Sean McCafferty

Sean McCafferty

McCafferty and colleagues conducted a prospective, randomized, double-blind, placebo-controlled study that included 1,000 eyes evenly delegated to the nonsteroidal anti-inflammatory drug or placebo cohort. Clinical PCME was defined as patients who lost two lines of best corrected visual acuity or had visually symptomatic distortion.

McCafferty reported that 308 eyes had risk factors and 692 eyes did not have those factors.

In addition to improving PCME outcomes in eyes with risk factors, McCafferty said the NSAID likely provided additional anti-inflammatory benefits. – by Robert Linnehan


McCafferty SJ. Pseudophakic cystoid macular edema prevention and risk factors: Prospective study with once-daily topical nepafenac 0.3% vs. placebo. Presented at: American Academy of Ophthalmology annual meeting; Oct. 14-18, 2016; Chicago, Ill.

Disclosure: McCafferty reported no relevant financial disclosures.